Compare JPMorgan Ultra Short Income ETF (JPST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Neurocrine Biosciences Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.49, while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| JPST | NBIX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.78 | $180.55 |
52-Week Low | $50.40 | $123.10 |
Market Cap | — | $17.40B |
Enterprise Value | — | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
